Update in Adrenocortical Carcinoma

Martin Fassnacht, Matthias Kroiss, and Bruno Allolio

Medizinische Klinik und Poliklinik IV (M.F.), Klinikum der Universität München, 80336 Munich, Germany; Comprehensive Cancer Center Mainfranken (M.F., M.K.), University of Würzburg, 97080 Würzburg, Germany; and Department of Internal Medicine I-Endocrine and Diabetes Unit (B.A.), University Hospital, University of Würzburg, 97080 Würzburg, Germany

Adrenocortical carcinoma (ACC) is an orphan malignancy that has attracted increasing attention during the last decade. Here we provide an update on advances in the field since our last review published in this journal in 2006.

The Wnt/β-catenin pathway and IGF-2 signaling have been confirmed as frequently altered signaling pathways in ACC, but recent data suggest that they are probably not sufficient for malignant transformation. Thus, major players in the pathogenesis are still unknown.

For diagnostic workup, comprehensive hormonal assessment and detailed imaging are required because in most ACCs, evidence for autonomous steroid secretion can be found and computed tomography or magnetic resonance imaging (if necessary, combined with functional imaging) can differentiate benign from malignant adrenocortical tumors. Surgery is potentially curative in localized tumors. Thus, we recommend a complete resection including lymphadenectomy by an expert surgeon. The pathology report should demonstrate the adrenocortical origin of the lesion (eg, by steroidogenic factor 1 staining) and provide Weiss score, resection status, and quantitation of the proliferation marker Ki67 to guide further treatment. Even after complete surgery, recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists as to whether all patients benefit from this therapy.

In advanced ACC, mitotane is still the standard of care. Based on the FIRM-ACT trial, mitotane plus etoposide, doxorubicin, and cisplatin is now the established first-line cytotoxic therapy. However, most patients will experience progress and require salvage therapies. Thus, new treatment concepts are urgently needed. The ongoing international efforts including comprehensive “-omic approaches” and next-generation sequencing will improve our understanding of the pathogenesis and hopefully lead to better therapies. (*J Clin Endocrinol Metab* 98: 4551–4564, 2013)

The interest in adrenocortical carcinoma (ACC) has increased tremendously in the last decade. In only 12 years, more literature has been published than in the 50 years before. Here we provide an update of the major advances in the field since our review published in the *JCEM* in 2006 (1). We performed a PubMed search of all articles published between January 2006 and June 2013 using the terms “adrenocortical carcinoma,” “adrenal cancer,” and “mitotane” (n = 985), and we screened the database at www.clinicaltrials.gov and abstracts of the annual meetings of The Endocrine Society and the American Society of Clinical Oncology (ASCO). We identified some 220 publications as most relevant, but due to space limitations, not all papers could be included. The recom
The recommendations of this review represent our personal view because the level of evidence in many areas of ACC remains low. However, we specifically acknowledge areas of particular uncertainty.

**Epidemiology**

ACC is a rare and highly aggressive malignancy with an annual incidence of 0.7–2.0 cases per million population (2, 3). ACC can occur at any age, with a peak incidence between 40 and 50 years, and women are more often affected (55–60%). The incidence in children is particularly high in southern Brazil due to the high prevalence (0.27%) of a specific TP53 germline mutation (R337H) (4).

**Molecular Pathogenesis**

The understanding of the molecular events underlying the pathogenesis of ACC has improved in recent years but is not yet satisfactory. Table 1 provides a selection of the most important molecular changes in ACC.

The two most frequent alterations observed in ACC so far are overexpression of IGF-2 (5–7) and constitutive activation of the Wnt/β-catenin pathway (8, 9). IGF-2 overexpression in sporadic ACC results mainly from duplication of the paternal allele (paternal unidisomy) and is associated with altered epigenetic imprinting at 11p15 (10). In vitro inhibition of IGF-2 signaling by blocking IGF-1 receptor agents reduced ACC cell proliferation (11). Activation of the Wnt/β-catenin pathway occurs in both adrenal adenomas and ACC (12–14) and is frequently caused by activating mutations of the gene encoding β-catenin (15). In patients with ACC, β-catenin activation—as confirmed by the presence of β-catenin nuclear staining—is associated with decreased overall survival (15, 16) indicating that this staining carries important clinical information. IGF-2 overexpression in transgenic animal models did not result in adrenal tumor development, although the IGF signaling pathway was activated (16, 17). Activation of the Wnt/β-catenin pathway in the adrenal cortex led to adrenal tumors, but only a few had malignant characteristics (8). Similarly, the combination of IGF-2 overexpression and Wnt activation induced only a slightly more malignant phenotype (16).

Steroidogenic factor 1 (SF1) plays an important role in adrenal development and is frequently overexpressed in adrenocortical tumors (18, 19). Furthermore, SF1 increases proliferation in human adrenocortical tumor cells (20), and high expression of SF1 in ACC is associated with poor survival (18, 21). Thus, SF1 may become an important therapeutic target because SF1 inverse agonists have been shown to inhibit adrenocortical cell proliferation in vitro (22).

Germline mutations in the TP53 tumor suppressor gene have been observed in 50–80% of children with ACC, indicating the presence of a Li-Fraumeni syndrome with susceptibility to a variety of further malignancies. A small number of mutations in mismatch repair genes have been associated with a Lynch syndrome phenotype (25). BUB1 and PINK1 high expression of BUB1 together with low expression of PINK1 (26) separates poor prognosis ACC from less aggressive tumors. Micro RNAs (eg, miR 483 5 p) possibly related to TARBP2 overexpression (29–31) can predict poor prognosis in ACC (32). High expression of Jag1 correlated with tumor grade and stage (28).

**Table 1. Genetic Alterations in ACC and Their Clinical Implications**

<table>
<thead>
<tr>
<th>Affected Genes</th>
<th>Alteration in ACC</th>
<th>Clinical Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>TP53</td>
<td>Germline mutation in children (60–80%) and adults (around 4%) (23, 24)</td>
<td>Li-Fraumeni syndrome with increased prevalence of other malignancies Poor prognosis</td>
</tr>
<tr>
<td></td>
<td>Somatic mutations (25–35%) and loss of heterozygosity in adult sporadic ACC</td>
<td>Occurs also in adenomas, aggressive phenotype in ACC (9, 16)</td>
</tr>
<tr>
<td>CTNNB1</td>
<td>Activating mutations or other activation of the Wnt/β-catenin pathway (8, 9, 15)</td>
<td>No clear relationship to prognosis due to almost uniform overexpression of IGF-2 (90% of cases)</td>
</tr>
<tr>
<td></td>
<td>Germline mutations in Beckwith-Wiedemann syndrome, paternal unisomy in sporadic ACC leading to high expression of IGF-2 (10)</td>
<td></td>
</tr>
<tr>
<td>11p15 locus (IGF-2, H19, CDKN1c)</td>
<td>Overexpression in both childhood and adult sporadic ACC (18, 19)</td>
<td>High expression is associated with impaired prognosis (18, 21)</td>
</tr>
<tr>
<td>SF1</td>
<td>Hypermethylation with low expression of tumor suppressor genes (33, 34)</td>
<td>Extensive hypermethylation negatively affects prognosis</td>
</tr>
<tr>
<td>CpG islands</td>
<td>Germline mutations in 3.2% of ACC cases (25)</td>
<td>Lynch syndrome</td>
</tr>
<tr>
<td>Mismatch repair genes</td>
<td>High expression of BUB1 together with low expression of PINK1 (26)</td>
<td>Separation of poor prognosis ACC from less aggressive tumors Predictors of prognosis, miR 483 5 p in serum may serve as biomarker for aggressive ACC (32)</td>
</tr>
<tr>
<td>BUB1 and PINK1</td>
<td>Altered expression profiles (eg, high miR 483 5 p) possibly related to TARBP2 overexpression (29–31)</td>
<td>Correlates with tumor grade and tumor stage</td>
</tr>
<tr>
<td>Micro RNAs</td>
<td>Up-regulation of both mRNA expression and protein levels (28)</td>
<td></td>
</tr>
<tr>
<td>Jag1</td>
<td>Up-regulation of both mRNA expression and protein levels (28)</td>
<td></td>
</tr>
</tbody>
</table>

The Endocrine Society. Downloaded from press.endocrine.org by [S(individualUserdisplayName)] on 07 February 2014 at 03:25 For personal use only. No other uses without permission. All rights reserved.
but significant percentage (~4%) of adult ACC patients (23, 24) carries a germline mutation in the TP53 gene, raising the question whether adults should be screened for TP53 mutations because this may impact on the future care of the affected patients and their relatives. Furthermore, somatic mutations of TP53 in tumor tissue or loss of heterozygosity at the TP53 locus is found in more than 50% of adult patients with ACC, and TP53 mutated tumors are associated with an aggressive phenotype (13). In a recent study, 3.2% of ACCs were associated with germline mutations of mismatch repair genes as part of the Lynch syndrome (25).

Gene expression profiling has further contributed to the understanding of the molecular pathogenesis of ACC. Unsupervised cluster analyses of transcriptome data permitted the identification of subgroups with different prognosis (26, 27). Furthermore, the expression of the two genes DLG7 and PINK1 allowed the discrimination of benign from malignant adrenocortical tumors, and the combined analysis of BUB1 and PINK1 identified subgroups of ACC with greatly differing prognoses.

Further pathways potentially involved in the pathogenesis of ACC include changes in Notch signaling (28) and alterations in adrenocortical microRNA profiles (29–31). Of note, high serum miR 483 5p was found to be a useful biomarker for poor prognosis ACC (32). In addition, hypermethylation of CpG islands has been observed in ACC compared to adrenal adenomas and was shown to lead to suppression of tumor suppressor genes and negatively affect the prognosis of ACC (33, 34).

### Diagnostic Workup

In recent years several reviews have covered the diagnostic workup of adrenal lesions (35–39). We therefore only summarize principles and highlight some recent advances.

#### Endocrine workup

In 2005, the European Network for the Study of Adrenal Tumors (ENSAT) suggested a preoperative laboratory workup for suspected ACC (www.ensat.org). It comprises assessment of basal cortisol, ACTH, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, androstenedione, testosterone, and estradiol as well as a dexamethasone suppression test and urinary free cortisol excretion. The aldosterone/renin ratio is measured in patients with hypertension or hypokalemia. Although the cost effectiveness of this approach is unproven, we still consider this extensive panel to be useful for several reasons: it may prove the adrenocortical origin of the lesion, suggest malignancy, and document autonomous glucocorticoid excess that, if missed, regularly entails postoperative adrenal failure. Autonomous hormone secretion can be expected in >80% of patients with ACC. However, routine use of the recently introduced urine steroid metabolomic analysis (40) might further increase this number and may serve as a fingerprint of the tumor, facilitating early detection of recurrence. In turn, there is a high likelihood that a large adrenal mass is not an ACC if autonomous steroid secretion is absent.

#### Imaging

Together with a careful endocrine workup, modern cross-sectional imaging is able to correctly diagnose an adrenal mass as ACC before surgery in most cases. Size is an obvious criterion to differentiate an adrenal mass because the median size of ACCs is >11 cm, whereas most adenomas are <5 cm. Tumors between 3 and 10 cm may be diagnostically challenging. Currently, no single imaging method can characterize with certainty a localized adrenal mass as ACC, but many studies in the last 15 years have established a threshold of ≤10 Hounsfield units (HU) in unenhanced computed tomography (CT) for the diagnosis of a benign adrenal lesion (for review, see Refs. 41 and 42). Because all series included only a few ACCs, we have now confirmed in 51 ACC cases that none had a density of less than 13 HU (43). However, CT with delayed contrast media washout using a cutoff of 50% washout and an absolute value of >35 HU after 10–15 minutes has superior diagnostic accuracy (44–47). State-of-the-art magnetic resonance imaging (MRI) including chemical shift and washout analysis is probably equally accurate, but the number of published studies is smaller (41, 42). In our experience, it is easier to obtain a standardized CT scan than an optimal MRI. Furthermore, preoperative CT can be easily combined with chest imaging for the presence of metastatic disease. Thus, we usually recommend CT if pregnancy can be excluded.

Ultrasound techniques (including contrast-enhanced methods) have not been thoroughly investigated but may be particularly valuable for the detection of liver metastases and during follow-up in selected patients (48).

In the difficult case, additional functional imaging is often helpful. With virtually no exception, ACCs have a high 18F-fluorodeoxyglucose uptake; however, this is also the case for most adrenal metastases, pheochromocytomas, and even some adenomas (49, 50). The adrenocortical origin of a lesion may be proven using metomidate tracers, which specifically bind to adrenocortical CYP11B enzymes, which catalyze the final steps of steroid synthesis (51). Thus, the specificity of this still experimental method is high, but recent data suggest that the sensitivity in ACC is lower than in adenomas (52).
All patients with suspected ACC require a chest CT scan for pulmonary metastases before surgery, which unfortunately is often neglected. Specific imaging of brain and bones is only needed in case of clinical suspicion. There is some evidence that 18F-fluorodeoxyglucose-positron emission tomography/CT might improve staging of the patients at initial diagnosis or during follow-up (50, 53, 54).

**Biopsy of an adrenal mass is usually not helpful**

In our experience, there is almost no role for a fine-needle biopsy in the diagnostic workup of an adrenal tumor because the diagnostic accuracy is often low (55) and violation of the tumor capsule may promote needle track metastases. The only two scenarios with a potential benefit comprise: 1) the few patients with metastatic disease not scheduled for surgery, in which other methods (eg, endocrine workup, metomidate imaging) have failed to establish the diagnosis; and 2) patients with a suspicious endocrine-inactive adrenal mass and a history of extra-adrenal malignancy, in whom the result would affect treatment.

**Follow-up investigations**

Recurrence is a frequent event even after complete resection, and the time to recurrence influences treatment decisions (see Recurrent ACC). Therefore, we recommend imaging every 3 months (CT of the chest and CT/MRI of abdomen) together with monitoring of steroid hormones initially found to be secreted by the tumor. After the first 2 years of follow-up, we gradually increase imaging intervals. However, we recommend follow-up in patients without evidence of disease for a minimum of 10 years after surgery. In patients with advanced disease, imaging intervals are guided by the treatment protocol.

**Areas of uncertainty: diagnostic workup**

- Will the urinary gas chromatography-mass spectrometry steroid profile prove to be of superior diagnostic accuracy at initial diagnosis and during follow-up?
- The best methods, time intervals of tumor evaluation, and the optimum duration of follow-up have never been studied.

**Histopathological diagnosis**

The histopathological diagnosis of adrenal tumors remains challenging; eg, the rate of incorrect initial histopathological diagnosis in Germany was 13% (56). Two major problems need to be addressed. First, the adrenocortical origin of the mass must be established. Here expression of SF1 has emerged as the most valid marker (18, 21, 57). Second, the discrimination of benign from malignant adrenocortical tumors requires the evaluation of multiple parameters. The Weiss score (58) is still the best-validated score and should be used for this purpose. Unfortunately, interobserver variability is rather high. A simplified score together with a structured training program may improve the reproducibility of the pathological diagnosis in the future (59–62). In addition, two large ENSAT studies demonstrated that the quantification of the proliferation marker Ki67 is highly important because Ki67 is the most powerful prognostic marker in both localized and advanced ACC (63, 64) to guide treatment decisions.

**Staging and prognosis**

Consensus has been obtained during the last 4 years that the tumor-staging classification suggested by ENSAT, which is a modification of the Lee classification from 1995, reliably predicts the outcome of patients (65, 66). In this staging system, stage 1 and stage 2 are defined as strictly localized tumors with a size of ≤5 cm or >5 cm, respectively. Stage 3 tumors are characterized by infiltration in surrounding tissue, positive regional lymph nodes, or a tumor thrombus in the vena cava/renal vein. Stage 4 is restricted to patients with distant metastasis. Although this staging system can differentiate patient cohorts with different prognosis and a 5-year stage-dependent survival of 81, 61, 50, and 13% (65), there is a need for further improvements; eg, by adding a grading system (63, 67). Molecular markers like matrix metalloproteinase type 2 (68), glucose transporter GLUT1 (69), SF1 (18), BUB1B and PINK1 (26) might help in the future, but none of them is yet validated.

**Treatment**

With the exception of one trial (70), treatment of ACC is based on nonrandomized trials or retrospective analyses. Therefore, the level of evidence for most recommendation is class II–IV. Whenever possible, patients should be treated within clinical trials (www.clinicaltrials.gov).

In all tumor stages, the adrenotoxic drug mitotane is of paramount importance and therefore is discussed separately.

**ACC amenable to radical resection (Figure 1A)**

Surgery is the single most important intervention in the treatment of nonmetastatic ACC. During the last 5 years there has been a lively debate on the best surgical approach to localized ACC. Although preoperative evidence of locally advanced disease undoubtedly requires open adrenalectomy, some groups have postulated that tumors with a diameter of <10 cm may be safely treated by laparoscopic adrenalectomy, whereas others are convinced that...
Figure 1. Treatment flow charts for patients with adrenocortical carcinoma. Consider always enrollment of patients in a clinical trial (for an updated list see www.clinicaltrials.gov). A, ACC amenable to radical resection. 1 All patients with stages I+II and most patients with stage III should be amenable to radical resection. If complete resection is not feasible, consider neoadjuvant treatment (eg, mitotane or cisplatin). In selected patients with single metastases, complete resection might be possible as well. 2 In patients with R2 resection, consider resurgery by an expert surgeon or see Figure 1C. 3 If Ki67 staining is not available, a high proliferative index (>5 mitoses/50 high-power fields) may be used for risk stratification. Patients with stage IV are judged as high-risk patients independent of Ki67. 4 www.adiuvo-trial.org. If inclusion is not possible, decide individually between observation only or adjuvant mitotane. 5 In some patients (eg, Ki67 >30% or large tumor thrombus in the vena cava), we consider additional cytotoxic therapy (eg, three cycles of cisplatin 80 mg/m²). 6 After 2 years, the time intervals are gradually extended. B, Recurrent ACC. Disease-free interval (DFI) is defined as time elapsed between initial surgery and date of recurrence. 1 To be judged by an expert multidisciplinary team, 2 or alternatively other local measures like radiofrequency ablation or chemoembolization, 3 by surgery or other local measures like radiofrequency ablation or chemoembolization, 4 even in case of mitotane naive, postinterventionally combined treatment with mitotane + cisplatin should be considered; 5 eg, three cycles of cisplatin (80 mg/m²) every 3 weeks. C, Advanced ACC. 1 Only in selected patients (eg, with severe hormone excess). 2 Alternatively, patients could be treated with an experimental therapy within a prospective clinical trial; 3 by clinical judgment: eg, rapidly progressing symptoms within <3 months, recurrence within 6 months after radical surgery, involvement of >2 organs, or Ki67 >30%. 4 If mitotane concentration at 3–4 weeks is <5 mg/L, consider adding EDP without delay because it is unlikely that this patient will reach a level >14 mg/L within the first 12 weeks of treatment. 5 In case of severe localized symptoms, consider local treatment like radiotherapy. 6 For the best currently available cytotoxic regimens see Supplemental Table 1 (published on The Endocrine Society’s Journals Online web site at http://jem.endojournals.org) and contact specialized center. Rx, resection with uncertain margins; R1, incomplete resection with microscopically positive margins; R2, incomplete resection with macroscopically positive margins; DFI, disease-free interval.
this carries an increased risk for recurrence. Because all studies are retrospective and methodologically disputable (71–75), no final conclusion can be drawn (76, 77). Open adrenalectomy should still be regarded as standard treatment for ACC, and laparoscopic surgery should be performed within a clinical trial or at least as part of an observational study.

More importantly, the extent of local resection and the experience of the surgeon may be key variables for the long-term outcome of surgery. Although no standard has been established concerning the extent of the first operation (78), the results of a recent retrospective analysis of 283 patients with stage I–III ACC suggest that locoregional lymph node dissection (LND) might improve both diagnostic accuracy and therapeutic outcome (79). In multivariate analyses, we found a significantly reduced risk for tumor recurrence (hazard ratio [HR], 0.65) and disease-related death (HR, 0.54) in LND patients when compared with no-LND patients. On the other hand, there seems to be little benefit of systematic ipsilateral nephrectomy in the absence of gross local invasion (80). However, to achieve a complete resection (R0 resection), locally involved organs or large veins should be resected en bloc, including tumor thrombus embolectomy (81, 82).

Irrespective of the surgical approach, we strongly recommend that surgery for ACC should be performed by a surgeon with long-standing experience in adrenal surgery. Although we acknowledge that there is no consensus about what qualifies an expert ACC surgeon, we propose—based on recent data (83, 84) and personal experience—that surgery for suspected ACC should be limited to surgeons with >20 adrenalectomies per year.

Adjuvant therapy

Although the natural rate of recurrence is uncertain (85, 86), there is no doubt that an effective adjuvant treatment would be of great benefit. The treatment modalities currently considered include mitotane, irradiation of the tumor bed, cytotoxic agents, or combinations of them. All available data are retrospective, but the most convincing results derive from a large retrospective analysis by Terzolo et al (87). In comparison to two independent control groups, patients with adjuvant mitotane had a significantly improved recurrence-free and overall survival (42 months vs 10 and 25 months, and 110 months vs 52 and 67 months, respectively). Nonetheless, it remains a matter of discussion, whether adjuvant mitotane is of long-term benefit for all patients (88, 89). This is particularly true for patients with presumably low or intermediate risk of recurrence, eg, defined by R0 resection, absence of metastases, and a Ki67 ≤ 10% (90). For this group of patients, we recommend inclusion in the international randomized ADIUVO trial (www adipiscing-trial.org) comparing mitotane with a strategy of watchful waiting.

External beam radiation therapy of the tumor bed might be a means to lower the high incidence of local recurrence. Currently there are three retrospective studies with 14, 10, and 16 patients plus corresponding controls, of which the first two showed a benefit in preventing local recurrence (91–93). None of them demonstrated an advantage for overall survival. Therefore, we currently recommend adjuvant radiotherapy only in case of particularly high risk for local recurrence, eg, R1 resection.

Data on adjuvant cytotoxic chemotherapy are scarce. The only study dates back to 2000 and investigated 17 patients treated with streptozotocin plus mitotane (94). In this nonrandomized study, it remained uncertain whether the positive effects were related to mitotane, streptozotocin, or the combination of both drugs. Other cytotoxic drugs have not been investigated in adult ACC in this setting, although we believe that a platinum-based adjuvant therapy might be of benefit for patients at very high risk of recurrence.

Based on the available data, we currently stratify patients according to their perceived risk of recurrence. Recent data from the ENSAT ACC study group indicate that resection status and Ki67 index are the most relevant prognostic parameters. As shown in Figure 1A, we define three risk groups and recommend treatment as indicated. In selected patients with very high risk, we consider additional treatment options. For instance, we would offer a patient with Ki67 > 30% and a large tumor thrombus in the vena cava a combination therapy of mitotane and three cycles of cisplatin (eg, 80 mg/m²).

Areas of uncertainty: localized disease

- Is clinical outcome in expert centers with >20 adrenalectomies per year superior compared to smaller centers?
- Is outcome after laparoscopic surgery comparable to open surgery in stage I–II ACC?
- Is LND required in all patients with suspected ACC?
- Is a combined adjuvant treatment (eg, mitotane + cisplatin) of benefit in a subset of high-risk patients?

Recurrent ACC (Figure 1B)

Although ACC recurrence is frequent, few data exist on the optimal management of recurrent ACC. Three recent papers describe the experience with chemoembolization, radiofrequency ablation, and surgical resection for liver metastases (80, 95, 96). Although all but one of these 76 patients experienced secondary recurrence, individual patients took advantage from these procedures. In 2011, two groups reported their results on pulmonary resection for
metastatic ACC in 24 and 26 patients (97, 98) and came to similar conclusions: pulmonary surgery might be useful in selected patients (eg, young patients with slowly progressing disease) because long-term disease control can be achieved in a subset of patients.

Based on the results of two recent studies in 45 and 154 patients with first recurrence (99, 100), we suggest the following approach (Figure 1B): surgery for recurrent ACC should be performed in patients with a disease-free interval of more than 12 months, in whom a complete resection is feasible. However, we advocate against surgery if the time between surgery and recurrence is less than 6 months. These patients are likely to benefit more from aggressive medical treatment. In all other patients, an individualized decision is required, and they may be candidates for a combined approach of medical therapy and ablative procedures.

**Advanced disease (Figure 1C)**

All patients not qualifying for a localized treatment who are in acceptable clinical condition require systemic therapy (for the best currently available regimens see Supplemental Table 1). Although there is significant heterogeneity even in advanced ACC (101, 102), the disease has a strong tendency toward rapid progression, and a stabilization for more than 3 months is a rare exception. The median survival in these patients in most series is about 12 months.

The only approved drug in advanced ACC is mitotane. Despite the lack of prospective, controlled trials, mitotane was already approved in the United States in 1970 and in Europe in 2004. Most data derive from retrospective series, and the objective response rate is at best 24% (103). Many years ago, the concept of targeting a certain mitotane plasma level was introduced (104, 105), and recently another retrospective study provided evidence that reaching a mitotane plasma level >14 mg/L is associated with improved overall survival (106).

Only the combination chemotherapy of etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been validated in a randomized controlled trial. This FIRM-ACT (First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment) trial included a total of 304 patients and compared EDP-M with streptozotocin and mitotane (Sz-M), both as first- and second-line cytotoxic treatment. Although overall survival was not significantly different (14.8 months, EDP-M; 12.0 months, Sz-M; HR, 0.79; P = .07), objective response rate and progression-free survival clearly favored EDP-M (23.2 vs 9.2%, P < .001; and 5.0 vs 2.1 months; HR, 0.55; P < .001). Furthermore, EDP-M was similarly effective in second-line therapy in patients failing Sz-M as first-line treatment. Therefore, it is tempting to speculate that the crossover design of the study attenuated the survival benefit of EDP-M. Due to these data and the fact that the rate of serious adverse events and quality of life during the treatment were comparable between the groups, most experts now advocate EDP-M as first-line therapy for patients requiring cytotoxic treatment (39, 107, 108).

However, the observation that EDP-M is similarly successful in first- and second-line therapy leads us to two main additional conclusions. 1) Based on a study by Assié et al (101), we select patients with presumably less aggressive disease (eg, slowly progressing tumor growth, only two involved organs, long disease-free interval after initial surgery) and treat them with mitotane monotherapy (Figure 1C). Based on a study by Mauclère-Denost et al (109), we increase the mitotane dosage within a few days to 6 g/d. We continue mitotane as monotherapy in patients with a mitotane concentration >8 mg/L after 3–4 weeks of treatment, and in patients with a blood level ≤5 mg/L we usually add EDP because the likelihood to reach a blood level >14 mg/L in a reasonable time frame is extremely low (110). In all other patients, we decide individually based on tolerability of mitotane and the clinical condition of the patient. 2) We believe that the FIRM-ACT results justify testing of new drugs as first-line treatment in selected patients with a presumed life expectancy of >6 months, allowing them to receive EDP-M in case of progression at first tumor evaluation. This concerns particularly targeted therapies because mitotane might diminish their antitumor efficacy by enhanced drug metabolism (111) (see also Mitotane: mechanism of action, pharmacokinetics, and management).

For patients failing EDP-M, only a limited number of regimens has been investigated. One is Sz-M (investigated as part of the FIRM-ACT study), but only about 15% of patients showed at least a stabilization for >6 months during this second-line treatment (M. Fassnacht, H. H. Mueller, B. Skogseid, unpublished data). Therefore, we currently offer our patients in this situation the combination of gemcitabine and capecitabine. As second-line chemotherapy, this combination achieved disease stabilization for at least 6 months in 8 of 28 patients (29%) (112). In patients with painful skeletal metastases, palliative radiotherapy is often of benefit (113). When the disease has progressed despite different cytotoxic treatments and a mitotane level >14 mg/L, it might be reasonable to stop mitotane to reduce the problem of drug interaction for subsequent therapies.

In case a given therapy is able to stabilize a progressive disease for at least 4 months, we reconsider surgery or other locoregional approaches.
Therefore, one of the main lessons from this trial is that sunitinib and other multi-TKI should preferentially be administered in patients without mitotane pretreatment or with dose adjustments of the respective TKIs.

Preliminary results have been reported during the 2013 ASCO meeting for the multi-TKI dovitinib (NCT01514526). Disease stabilization >6 months has been observed in 23% of 17 ACC patients (121).

Only recently drugs targeting IGF-2, the most up-regulated gene in ACC, and its receptor IGF-1R became clinically available. Activity of IGF-1R antagonists has been demonstrated in vitro and in a xenograft model of ACC (11). Results of phase I trials with the highly specific IGF-1R inhibitor lisitinib (OSI-906) were promising and led to the first industry-sponsored, randomized, placebo-controlled, double-blind phase III clinical trial in ACC (GALACCTIC, NCT00924989). A total of 138 patients have been enrolled, and results are expected to be published by 2014.

In an extended phase I trial with the IGF-1R antibody cixutumab in combination with temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), one of the downstream targets of IGF-1R signaling, 26 patients with advanced ACC have been treated. In 11 of these patients (42%), disease stabilization for 6 months or longer has been observed (122). However, targeting mTOR alone using everolimus resulted in no meaningful response in four patients (123).

Areas of uncertainty: recurrent and advanced disease

- Is surgery of the primary tumor or debulking surgery in general of benefit or harm in patients with metastatic ACC?
- Which patients are candidates for mitotane monotherapy?
- For which combination therapies is concomitant mitotane beneficial?
- When should mitotane treatment be stopped in progressing disease?

Targeted therapies and salvage treatment

Current treatment concepts fail in many patients with advanced ACC. This stimulated interest in molecular-targeted therapies (Table 2). The first trials targeted the epidermal growth factor receptor, but both gefitinib (114) and the combination of erlotinib and gemicitabine (115) did not lead to promising results.

Targeting of tumor vasculature has attracted more attention in ACC because vascular endothelial growth factor (VEGF) and its receptor VEGF-R2 have been demonstrated to be highly expressed in ACC (116), and antiangiogenic drugs exhibited modest antitumor effects in preclinical tumor models (117, 118). However, bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with capectabine did not yield any tumor response (n = 10) (119). Similarly, the multi-tyrosine kinase inhibitor (TKI) sorafenib in combination with paclitaxel failed to demonstrate clinical efficacy in nine ACC patients (120).

Among the VEGF-targeting TKIs, only sunitinib has demonstrated modest antitumor effects in a phase II clinical trial (111). The primary endpoint of progression-free survival at 12 weeks was met by five patients (14.3%). In this trial, we confirmed that concomitant mitotane treatment strongly diminished plasma levels of sunitinib and its active metabolite. Therefore, one of the main lessons from this trial is that sunitinib and other multi-TKI should preferentially be administered in patients without mitotane pretreatment or with dose adjustments of the respective TKIs.

Preliminary results have been reported during the 2013 ASCO meeting for the multi-TKI dovitinib (NCT01514526). Disease stabilization >6 months has been observed in 23% of 17 ACC patients (121).

Only recently drugs targeting IGF-2, the most up-regulated gene in ACC, and its receptor IGF-1R became clinically available. Activity of IGF-1R antagonists has been demonstrated in vitro and in a xenograft model of ACC (11). Results of phase I trials with the highly specific IGF-1R inhibitor lisitinib (OSI-906) were promising and led to the first industry-sponsored, randomized, placebo-controlled, double-blind phase III clinical trial in ACC (GALACCTIC, NCT00924989). A total of 138 patients have been enrolled, and results are expected to be published by 2014.

In an extended phase I trial with the IGF-1R antibody cixutumab in combination with temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), one of the downstream targets of IGF-1R signaling, 26 patients with advanced ACC have been treated. In 11 of these patients (42%), disease stabilization for 6 months or longer has been observed (122). However, targeting mTOR alone using everolimus resulted in no meaningful response in four patients (123).

Overall, it appears that using only one drug may not suffice to induce an objective response. Although enthusiasm toward IGF-1R antagonists in general has markedly decreased, we—not only due to impressive tumor responses in individual patients—still believe that ACC is a malignancy in which this class of drugs, probably in combination with other drugs, holds therapeutic potential.

Our group has recently developed a radionuclide therapy based on [131I]iodometomidate, and we have applied this method on a compassionate-use basis in 11 patients with advanced, progressing ACC (124). In one patient, a decrease of tumor burden of some 50% lasting for 26 months has been demonstrated, and five additional pa-

### Table 2. Published Experience With Targeted Therapies

<table>
<thead>
<tr>
<th>Agents</th>
<th>Rationale</th>
<th>n</th>
<th>Outcome</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunitinib</td>
<td>Multi-TKI (VEGFR, PDGFRβ, c-kit, FLT3, RET)</td>
<td>35</td>
<td>5 stable disease</td>
<td>111</td>
</tr>
<tr>
<td>Cixutumab + temsirolimus</td>
<td>IGF-1R antibody + mTOR inhibitor</td>
<td>26</td>
<td>11 stable disease</td>
<td>122</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>Inhibition of EGFR signaling</td>
<td>19</td>
<td>No response</td>
<td>114</td>
</tr>
<tr>
<td>Dovitinib</td>
<td>Multi-TKI (FGFR, PDGFR, VEGFR)</td>
<td>17</td>
<td>4 stable disease</td>
<td>121</td>
</tr>
<tr>
<td>Bevacizumab + capecitabine</td>
<td>Inhibition of VEGF signaling + cytotoxic drug</td>
<td>10</td>
<td>No response</td>
<td>119</td>
</tr>
<tr>
<td>Erlotinib + gemcitabine</td>
<td>Inhibition of EGFR signaling + cytotoxic drug</td>
<td>10</td>
<td>1 stable disease</td>
<td>115</td>
</tr>
<tr>
<td>Sorafenib + paclitaxel</td>
<td>Multi-TKI (BRAF, VEGFR, c-kit, PDGFRβ) + cytotoxic drug</td>
<td>9</td>
<td>No response</td>
<td>120</td>
</tr>
<tr>
<td>Imatinib</td>
<td>Inhibition of c-KIT and PDGFR</td>
<td>4</td>
<td>No response</td>
<td>140</td>
</tr>
<tr>
<td>Everolimus</td>
<td>mTOR inhibitor</td>
<td>4</td>
<td>No response</td>
<td>123</td>
</tr>
</tbody>
</table>

*a* Only studies reporting at least three patients have been included.

*b* Published only as abstract.
patients experienced stable disease, lasting in three for at least 10 months.

All other targeted treatment approaches are still in a preclinical stage. From our perspective, the following concepts merit further investigations: inhibition of heat shock protein 90 (125), the proteasome inhibitor bortezomib (126), and targeting SF1 (22).

Other salvage therapies are based primarily on small series like oral etoposide and oral cyclophosphamide (127) or case reports (128, 129).

Overall, the poor efficacy of several classes of targeted therapies has markedly dampened expectations of ACC tumor control in metastatic disease.

Mitotane: mechanism of action, pharmacokinetics and management

As described in the sections Adjuvant therapy and Advanced ACC, mitotane is currently the cornerstone of medical treatment for ACC. It is given orally in 500-mg tablets (Lysodren; HRA Pharma Paris, Bristol-Myers Squibb). De-

<table>
<thead>
<tr>
<th>Table 3. Recommendations on Mitotane Management</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiation of treatment</td>
<td>Optimal distribution of mitotane during the day has not been studied; thus we respect patient preference.</td>
</tr>
<tr>
<td>High-dose regime</td>
<td>Preferred regimen for monotherapy.</td>
</tr>
<tr>
<td>Low-dose regime</td>
<td>For patients with reduced clinical conditions and in combination therapy.</td>
</tr>
<tr>
<td>Drug monitoring</td>
<td>Check every 3–4 wk during the first 6 months, then intervals might be prolonged.</td>
</tr>
<tr>
<td>Mitotane plasma level</td>
<td>14–20 mg/L; in patients without adverse effects plasma levels &gt;20 mg/L can be accepted.</td>
</tr>
<tr>
<td>Target plasma level</td>
<td>Bone marrow toxicity is rare, but agranulocytosis might be life-threatening.</td>
</tr>
<tr>
<td>Safety parameters</td>
<td>GGT is invariably elevated without clinical consequences.</td>
</tr>
<tr>
<td>GOT, GPT, bilirubin (GGT)</td>
<td>Check initially every 3–4 wk, after 6 months every 8 wk. If GPT/GPT increase &gt;3-fold ULN, interrupt mitotane treatment.</td>
</tr>
<tr>
<td>Blood count</td>
<td>Bone marrow toxicity is rare, but agranulocytosis might be life-threatening.</td>
</tr>
<tr>
<td>Cholesterol (HDL, LDL), triglycerides</td>
<td>Lipid alterations occur frequently.</td>
</tr>
<tr>
<td>Hormonal changes and hormone replacement</td>
<td>Replacement is needed only in a subset of patients.</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Due to accelerated metabolism (CYP3A4 induction) and increased cortisol-binding globulin, a high hydrocortisone replacement dosage is required (in the long run, average dosage 40–60 mg/d).</td>
</tr>
<tr>
<td>Mineralocorticoids</td>
<td>Replacement is needed only in a subset of patients.</td>
</tr>
<tr>
<td>Androgens</td>
<td>Due to CYP3A4 induction, increased SHBG, and inhibition of 5α reductase, hypogonadism is frequent (but clinically variable).</td>
</tr>
<tr>
<td>Oral contraception</td>
<td>CYP3A4 induction leads to increased clearance and reduced efficacy (and estrogens might play a role in ACC tumorigenesis).</td>
</tr>
<tr>
<td>Thyroid hormones</td>
<td>Alternations of thyroid hormones are frequent, but variable (and not yet fully elucidated).</td>
</tr>
<tr>
<td>Selection of other relevant drug interactions</td>
<td>Examples of drugs metabolized by CYP3A4.</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Calcium antagonists. Use instead ACE inhibitors, β-blockers, α-blockers, angiotensin 2-antagonists, diuretics.</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>Most HMG-CoA reductase inhibitors (eg, atorvastatin, cerivastatin, lovastatin, simvastatin). Use pravastatin or rosuvastatin.</td>
</tr>
<tr>
<td>Insomnia, agitation</td>
<td>Benzodiazepines (eg, midazolam, diazepam), Z-drugs (eg, zopiclone, zolpidem). For many cases, no alternatives are available. Consider increased dosage.</td>
</tr>
<tr>
<td>Infection</td>
<td>Some macrolide antibiotics (eg, erythromycin, clarithromycin). Use alternative antibiotics like azithromycin, moxifloxacin, ciprofloxacin.</td>
</tr>
<tr>
<td>Analgesia</td>
<td>Some opioids (eg, fentanyl, methadone, oxycodone, tramadol). Use instead morphine or hydromorphone.</td>
</tr>
</tbody>
</table>

GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; GGT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ULN, upper limit of normal; ACE, angiotensin-converting-enzyme; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A.
spite its use for more than 50 years, little is known about the molecular mechanism of mitotane action, and some observations, such as binding of mitotane to a protein receptor, have not been conclusively confirmed. Recent data suggest that down-regulation of mitochondrial respiratory chain is involved (130, 131), but the pathway leading to these changes has not been clarified, even using high-throughput techniques such as gene expression microarrays and proteome profiling (30, 132, 133).

Like the mechanism of action, pharmacokinetic data are limited. Nested in the FIRM-ACT trial, a study on the pharmacokinetics of mitotane investigated the relationship between mitotane dose and plasma concentration comparing two dosing regimens (110). Surprisingly, a “high-dose starting regimen” only led to a small, nonsignificant difference in mitotane levels with a similar rate of adverse events. Only among patients not receiving concomitant cytotoxic treatment was a clear trend toward higher mitotane exposure in the high-dose group (area under the curve 0–12 weeks: 1013 vs 555 mg per dL; \(P = 0.080\)). However, the variability of individual plasma levels reached by a given dosage is high, and it remains unclear which enzymes metabolize mitotane in humans, although there is first evidence that CYP2B6 might be involved (134). Several studies have demonstrated that a mitotane plasma level >14 mg/L is required for clinical efficacy of the drug (104–106), making regular monitoring of the drug level mandatory. Of note, this concept has also been introduced very recently in the adjuvant setting (135).

The recent observation of a strong and sustained induction of cytochrome P450 3A4 (CYP3A4) by mitotane (136) has now been confirmed using a steroidomics approach (137). The induction of CYP3A4 has a major impact on the care of ACC patients because mitotane is one of the strongest CYP3A4 inducers, lowering the blood levels of many drugs frequently coadministered with mitotane (including but not limited to steroids, antihypertensives, and antibiotics) (138). A list of drugs with a high potential of interaction is nested in Table 3.

Mitotane comes with significant toxicity, and patients should be monitored closely by an experienced physician. The incidence and severity of adverse drug effects have only been systematically evaluated in a few cohorts (109, 110, 139). However, dizziness, vertigo, and other central nervous system disturbances are common, and virtually all patients suffer some kind of gastrointestinal symptoms requiring active management with antiemetics and loperamide as individually indicated. Although grade 3/4 toxicity is overall rare, we have seen life-threatening agranulocytosis and liver failure in single patients. In contrast, in virtually all patients, a strong elevation of the \(\gamma\)-glutamyltransferase is detectable, which in our view is clinically not relevant. Furthermore, all patients develop adrenal insufficiency, which has to be replaced with a high dosage of hydrocortisone (due to the induction of CYP3A4 with increased metabolism of cortisol and increased cortisol-binding globulin).

**Areas of uncertainty: targeted therapy and mitotane management**

- Which combinations of molecular-targeted drugs are most useful to combat advanced ACC?
- Which drugs could be usefully combined with mitotane despite mitotane-induced CYP3A4 activity?
- Are there means to reduce mitotane-induced CYP3A4 activity?

**Future Perspectives**

Despite advances in the molecular pathogenesis of ACC, the initiating and driving mutations remain incompletely understood, but are of key importance for the development of better treatments. Here international efforts are under way to provide a comprehensive molecular analysis including whole genome sequencing in a large number of ACC cases. Urinary steroid profiling seems to be a promising diagnostic tool; however, its true value has to be demonstrated in large-scale prospective, multicenter trials. Concerning surgery, the time has come for randomized trials to assess the best operation strategy (eg, with or without LND). We expect that the ADIUVO trial will shed further light on the value of adjuvant mitotane in ACC. A better understanding of the molecular action of mitotane is urgently needed now to allow prediction of the individual response to this difficult drug and as a prerequisite for the development of less toxic compounds. Although targeted therapies have been largely disappointing in advanced ACC, this may be in part related to insufficient drug levels due to concomitant or previous mitotane administration and to the fact that they were mostly studied as salvage therapy in refractory disease. The occasional impressive response to inhibition of IGF-1 signaling indicates its therapeutic potential, but it probably needs to be combined with other drugs for optimum activity. Furthermore, earlier use of targeted therapies might lead to improved results without jeopardizing the efficacy of later cytotoxic therapy. Currently, only four intervention trials are recruiting patients (NCT01832974, NCT01048892, NCT00777244, and NCT01898715). Therefore, it is the task of the ACC community to convince public stakeholders and pharmaceutical companies to make a stronger commitment for clinical trials in ACC. However, the highly successful international cooperation in the fight
against this dreadful disease that was triggered by the EN-SAT and the FIRM-ACT consortium has undoubtedly set the stage for major progress in the coming decade.

**Acknowledgments**

Address all correspondence and requests for reprints to: Prof Dr Martin Fassnacht, Department of Internal Medicine IV, Hospital of the University of Munich, Ziemssenstrasse 1, 80336 München, Germany. E-mail: martin.fassnacht@med.uni-muenchen.de.

This work was supported by Deutsche Forschungsgemeinschaft Grants FA 466/4-1 (to M.F.) and KR 4371/1-1 (to M.K.) and the European Union (Seventh Framework Programme [FP7/2007–2013] under Grant Agreement 259735) (to M.F. and B.A.).

Disclosure Summary: The authors received support for a clinical trial from Pfizer Pharma and participated in a pharmacokinetic trial on mitotane sponsored by HRA Pharma and a trial on OSI-906 sponsored by Astellas Pharma.

**References**


72. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open ad-


